Application of the Continuous Rheoconversion Process (CRPTM) to Low Temperature HPDC-Part II: Alloy Development & Validation

Stuart Wiesner; Qin Yue Pan; Diran Apelian

doi:10.4028/www.scientific.net/SSP.116-117.64

Paper Titles

Semi Solid Casting and Forging of Steel
p.34

Development of an Advanced Rheocasting Process and Its Applications
p.44

Determination of Solidification Parameters Used for the Prediction of the Thixoformability of Several Steel Alloys
p.54

Design and Production of New Aluminum Thixotropic Alloys for the Manufacture of Structural Components by Semisolid Die Casting
p.58

Application of the Continuous Rheoconversion Process (CRP^TM) to Low Temperature HPDC-Part II: Alloy Development & Validation
p.64

Development of Heat Resistant Mg-Al-Ca Based Alloys for Casting and Semi-Solid Forming
p.68

Thixoforming and Industrial Application of the Semi-Solid Alloy Al-6Si-2Mg
p.72

Hot Tearing Susceptibility and Fluidity of Semi-Solid Gravity Cast Al-Cu Alloy
p.76

Anodic Oxide Layer Formation on A357 Aluminium Alloy Produced by Thixocasting
p.80

HomeSolid State PhenomenaSolid State Phenomena Vols. 116-117Application of the Continuous Rheoconversion...

Application of the Continuous Rheoconversion Process (CRP^TM) to Low Temperature HPDC-Part II: Alloy Development & Validation

Abstract:

The continuous rheoconversion process (CRPTM) is a novel slurry-on-demand process that was developed at MPI/WPI in 2002. The process is based on a passive liquid mixing technique in which the nucleation and growth of the primary phase are controlled using a specially designed “reactor”. The reactor provides heat extraction, copious nucleation, and forced convection during the initial stage of solidification, thus leading to the formation of globular structures. This paper presents our recent work on the scale-up of the CRPTM for industrial applications. In Part II of this paper, we present salient results on alloy optimization via thermodynamic simulations, as well as validation results obtained from industrial Beta trials.